Talapro-3 could help move Talzenna into earlier prostate cancer.
ApexOnco Front Page
Recent articles
Single, double and even triple-payload ADCs will be presented at the meeting.
Bristol will advance the newest pivotal trials, in first-line colorectal and gastric cancers.
Syndax’s Revuforj beats Kura in NPM1-mutated AML.
As tinkering with HLA matching continues, is nearly as good as Breyanzi good enough?
But the extensively curated dataset covering its anti-PD-L1 ADC raises more questions.
The group is expanding its mRNA-4359 trial to include first-line melanoma.
FDA decisions loom for Kura’s ziftomenib and Bayer’s sevabertinib.
